Mariacarla Andreozzi
YOU?
Author Swipe
View article: Association of Axillary Lymph Node Dissection with Oncological Outcomes in Patients with Residual Micrometastases after Neoadjuvant Chemotherapy: The OPBC-07/microNAC Study
Association of Axillary Lymph Node Dissection with Oncological Outcomes in Patients with Residual Micrometastases after Neoadjuvant Chemotherapy: The OPBC-07/microNAC Study Open
View article: Nodal Burden and Oncologic Outcomes in Patients With Residual Isolated Tumor Cells After Neoadjuvant Chemotherapy (ypN0i+): The OPBC-05/ICARO Study
Nodal Burden and Oncologic Outcomes in Patients With Residual Isolated Tumor Cells After Neoadjuvant Chemotherapy (ypN0i+): The OPBC-05/ICARO Study Open
PURPOSE The nodal burden of patients with residual isolated tumor cells (ITCs) in the sentinel lymph nodes (SLNs) after neoadjuvant chemotherapy (NAC) (ypN0i+) is unknown, and axillary management is not standardized. We investigated rates …
View article: Impact of Imaging-Guided Localization on Performance of Tailored Axillary Surgery in Patients with Clinically Node-Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)
Impact of Imaging-Guided Localization on Performance of Tailored Axillary Surgery in Patients with Clinically Node-Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101) Open
Background Tailored axillary surgery (TAS) is a novel surgical concept for clinical node-positive breast cancer. It consists of the removal of the sentinel lymph nodes (LNs), as well as palpably suspicious nodes. The TAS technique can be u…
View article: Association of Axillary Dissection With Systemic Therapy in Patients With Clinically Node-Positive Breast Cancer
Association of Axillary Dissection With Systemic Therapy in Patients With Clinically Node-Positive Breast Cancer Open
Importance The role of axillary lymph node dissection (ALND) to determine nodal burden to inform systemic therapy recommendations in patients with clinically node (cN)–positive breast cancer (BC) is currently unknown. Objective To address …
View article: Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)
Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101) Open
Purpose The aim of this study was to evaluate clinical practice heterogeneity in use of neoadjuvant systemic therapy (NST) for patients with clinically node-positive breast cancer in Europe. Methods The study was preplanned in the internat…
View article: Uncertainties and controversies in axillary management of patients with breast cancer
Uncertainties and controversies in axillary management of patients with breast cancer Open
View article: Supplementary Figures 1-10 from Human and Mouse <i>VEGFA</i>-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment
Supplementary Figures 1-10 from Human and Mouse <i>VEGFA</i>-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment Open
PDF file 1687K, The supplementary data contains immunostains, mRNA and DNA qPCR, ELISA analyses and descriptive cartoons including a model highlighting the manuscript
View article: Supplementary Tables from Human and Mouse <i>VEGFA</i>-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment
Supplementary Tables from Human and Mouse <i>VEGFA</i>-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment Open
PDF file 145K, Tables containing information about genes residing on the amplicon and compiled data
View article: Data from Human and Mouse <i>VEGFA</i>-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment
Data from Human and Mouse <i>VEGFA</i>-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment Open
Death rates from hepatocellular carcinoma (HCC) are steadily increasing, yet therapeutic options for advanced HCC are limited. We identify a subset of mouse and human HCCs harboring VEGFA genomic amplification, displaying distinct b…
View article: Supplementary Tables from Human and Mouse <i>VEGFA</i>-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment
Supplementary Tables from Human and Mouse <i>VEGFA</i>-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment Open
PDF file 145K, Tables containing information about genes residing on the amplicon and compiled data
View article: Data from Human and Mouse <i>VEGFA</i>-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment
Data from Human and Mouse <i>VEGFA</i>-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment Open
Death rates from hepatocellular carcinoma (HCC) are steadily increasing, yet therapeutic options for advanced HCC are limited. We identify a subset of mouse and human HCCs harboring VEGFA genomic amplification, displaying distinct b…
View article: Supplementary Figures 1-10 from Human and Mouse <i>VEGFA</i>-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment
Supplementary Figures 1-10 from Human and Mouse <i>VEGFA</i>-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment Open
PDF file 1687K, The supplementary data contains immunostains, mRNA and DNA qPCR, ELISA analyses and descriptive cartoons including a model highlighting the manuscript
View article: Unique evolutionary trajectories of breast cancers with distinct genomic and spatial heterogeneity
Unique evolutionary trajectories of breast cancers with distinct genomic and spatial heterogeneity Open
Breast cancers exhibit intratumoral heterogeneity associated with disease progression and therapeutic resistance. To define the sources and the extent of heterogeneity, we performed an in-depth analysis of the genomic architecture of three…
View article: Corrigendum to “HMGA1 expression in human hepatocellular carcinoma correlates with poor prognosis and promotes tumor growth and migration in in vitro models” [Neoplasia 18 (2016) 724–731]
Corrigendum to “HMGA1 expression in human hepatocellular carcinoma correlates with poor prognosis and promotes tumor growth and migration in in vitro models” [Neoplasia 18 (2016) 724–731] Open
View article: JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer
JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer Open
These data suggest that the JAK2/STAT1 pathway in TNBC might regulate the dynamic expression of PD-L1 that is induced in the setting of an inflammatory response. Inhibition of JAK2 might provide a synergistic therapy when combined with oth…
View article: Development and validation of a novel clinical fluorescence in situ hybridization assay to detect JAK2 and PD-L1 amplification: a fluorescence in situ hybridization assay for JAK2 and PD-L1 amplification
Development and validation of a novel clinical fluorescence in situ hybridization assay to detect JAK2 and PD-L1 amplification: a fluorescence in situ hybridization assay for JAK2 and PD-L1 amplification Open
View article: Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes
Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes Open
VEGFA is an angiogenic factor secreted by tumors, in particular those with VEGFA amplification, as well as by macrophages and lymphocytes in the tumor microenvironment. Here we sought to define the presence of M1/M2 macrophages, PD-1-posit…
View article: HMGA1 Expression in Human Hepatocellular Carcinoma Correlates with Poor Prognosis and Promotes Tumor Growth and Migration in in vitro Models
HMGA1 Expression in Human Hepatocellular Carcinoma Correlates with Poor Prognosis and Promotes Tumor Growth and Migration in in vitro Models Open
HMGA1 is frequently expressed in cirrhotic tissues and HCCs and its expression is associated with high Edmondson grade and worse prognosis in HCC. Our results suggest that HMGA1 may act as oncogenic driver of progression, implicating it in…
View article: CD55 is a HIF-2α marker with anti-adhesive and pro-invading properties in neuroblastoma
CD55 is a HIF-2α marker with anti-adhesive and pro-invading properties in neuroblastoma Open
View article: Genomic amplification of 9p24.1 targeting <i>JAK2</i>, <i>PD-L1</i>, and <i>PD-L2</i> is enriched in high-risk triple negative breast cancer
Genomic amplification of 9p24.1 targeting <i>JAK2</i>, <i>PD-L1</i>, and <i>PD-L2</i> is enriched in high-risk triple negative breast cancer Open
We used DNA content flow cytometry followed by oligonucleotide array based comparative genomic hybridization to survey the genomes of 326 tumors, including 41 untreated surgically resected triple negative breast cancers (TNBC). A high leve…